Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program
Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.